Xellia Pharmaceuticals

We are pleased to announce that the divestment of our US institutional business to Hikma Pharmaceuticals has been completed, following clearance under applicable US antitrust laws. The transaction includes the Cleveland, Ohio, USA manufacturing site, the in-market institutional, commercial portfolio based in Chicago, Illinois, USA, the drug product R&D pipeline, and the majority of our R&D site in Zagreb, Croatia. The divestment follows a strategic decision to concentrate on the manufacturing and commercializing of fermentation-based anti-infective APIs (Active Pharmaceutical Ingredients) combined with a selected offering of FDFs (Finished Dosage Forms) to the global markets via the B2B sales channel. Michael Kocher, CEO at Xellia Pharmaceuticals, said:  "This is a defining milestone in the transformation journey we embarked on less than a year ago. By focusing on our core strengths, we are positioning Xellia for a robust and prosperous future, enabling us to continue to deliver life-saving products to patients worldwide." Click here to read more - https://bit.ly/4gmixlp

Strategy update! Today we are announcing the divestment of our US institutional business to Hikma Pharmaceuticals, marking a significant milestone in the transformation journey we embarked on almost nine months ago. The transaction, subject to customary closing conditions, will see Hikma acquire our US institutional sales-related operations, including our Cleveland manufacturing site, our commercial portfolio based in Chicago, our R&D pipeline and our R&D site in Zagreb, Croatia. The transaction follows a strategic decision to concentrate on the manufacturing and commercializing of fermentation-based APIs (Active Pharmaceutical Ingredients) for anti-infectives combined with a selected offering of FDFs (Finished Dosage Forms) to the global markets via the B2B sales channel. This strategic pivot will pave the way for a resilient and prosperous future for Xellia, ensuring continued supply of our life-saving products to patients worldwide. Click here to read more - https://bit.ly/4etmhRa

Exciting update! The US Court has lifted the rules imposed on our Cleveland, Ohio facility! Originally set by the FDA and the former owner, the rules were specific to the site's manufacturing operations. Since Xellia took over in 2015, we've been following these rules closely, undergoing regular inspections. And in March 2024, we got a thumbs-up from the FDA, showing we're doing things right. Our Cleveland team has done an amazing job, and we're grateful for their hard work. This is a big win for us and shows our commitment to quality. Let’s keep up the great work! Read the full press release here – https://bit.ly/3UA4Wya #xellia #quality #compliance #xelliacleveland #milestone

Last autumn, six colleagues from our Copenhagen, Oslo and Zagreb sites visited SOS Children’s Villages in Eldoret, Kenya. It was a privilege to meet the families who we have helped through our nine-year long corporate partnership and employee-driven initiatives. During our visit, we connected with families enrolled in the Family Strengthening Program. Witnessing how these initiatives empower vulnerable families to build stable homes and care for their children was truly inspiring. By providing start-up capital and solar support, we've helped boost income-generating activities and improve living conditions. Seeing the impact of our collaborative efforts left us feeling grateful! A heartfelt thank you to SOS Children’s Villages Kenya for hosting us, and to SOS Children's Villages Denmark for our fruitful partnership! #fundraising #givingbacktosociety #SOSChildrensVillages #xellia #SOSBørnebyerne

Meet us in Austin, Texas, U.S., at the 2024 National Home Infusion Association (NHIA) Annual Conference on March 23rd-27th. Our sales team can’t wait to meet with you. If you’d like to know more about Xellia representation at the conference, reach out to us at [email protected]. See you there!

Meet us in New York City at #DCATWeek! We're looking forward to engaging in insightful conversations, connecting with industry peers and exploring new opportunities to better serve our valued customers and partners.

At Xellia, we aim to cultivate an inclusive environment where everyone, regardless of gender, can thrive and contribute to our success. Today, as we commemorate International Women's Day, we reflect not only on our progress but also on the work that still lies ahead. There is still some way to go to reach our ambitious ESG targets to drive greater gender equality in Xellia, including a commitment that by 2030, 45% of managerial positions at Xellia will be held by women. Today, our global gender diversity stands at 43% female and 57% male, with female representation among our leaders at 36%. We seek to improve this balance as we recognize women's pivotal role in driving progress and excellence in Xellia. Research shows that companies with diverse leadership teams outperform their counterparts – greater gender diversity among senior leaders fosters innovation and ultimately leads to increased profitability. "I am proud of Xellia's talented women workforce, from the 'shop floor' to our leadership teams. We are committed to fostering a culture of equity and inclusivity at all Xellia sites. Embracing gender diversity is essential to remaining a relevant and attractive place to work - it's simply the right thing to do," Michael Kocher, CEO, says. #IWD2024 #InspireInclusion #DiversityEquityInclusion #genderequality #xellia

Meet us in Orlando, Florida, U.S., at the 2024 Managed Healthcare Associates (MHA) Business Summit on March 4th-6th. Our sales team can’t wait to meet with you. If you’d like to know more about Xellia representation at the conference, reach out to us at [email protected]. See you there!

Today, on International Day of Women and Girls in Science, we celebrate the incredible contributions of women in #STEM fields. It is a reminder to break down gender barriers and promote equal access to participate in science. With our 120-year heritage in the pharma industry, focusing on the reliable supply of high-quality anti-infectives and critical care therapies, Xellia is deeply rooted in science and committed to diversity, equity and inclusion. We recognize women’s pivotal role in driving progress and excellence within our organization. While we celebrate Xellia’s female talents, we use this occasion to highlight the unique achievement of two female inventors in our R&D department. They share insights into being an inventor and advice to other women in pursuit of a career in science. Barbara Fumić, Xellia Zagreb – “Curiosity has been the greatest drive in my career. I believe that only those who look for a solution will find one. For me, being an inventor means being unique and different in a world of conformity. If you always try to be normal, you will never know how amazing you can be.” Anita Bevetek Moćnik, Xellia Zagreb – “You can work diligently in the industry for years and still be humbled by new projects – this is fascinating. My advice? Not everything is as it appears at first sight, either in science or in life. When a bump occurs on the way, take a moment to consider if there is a lesson to learn or if you should adjust your plan. When deciding, breathe and be brave to stay true to yourself!” Join us in celebrating our #WomenInScience – their accomplishments and dedication! #InternationalDayofWomenandGirlsinScience #DiversityEquityInclusion #stemcareers #xellia

We extend our warmest wishes to our global network of colleagues, customers and business partners who celebrate Lunar New Year. May the year ahead be marked by boundless health, happiness and prosperity. Here’s to another year of fruitful collaboration and shared success! #lunarnewyear2024 #yearofthedragon #xellia